Xelios Biometrics and ScriptPro sign licensing agreement

August 7, 2013 - 

Xelios Biometrics and ScriptPro have just struck a multi-year licensing agreement under which, Xelios will provide biometric authentication technology for ScriptPro’s pharmacy automation and management systems.

Xelios Biometrics is a supplier of biometric identity solutions, which are based on technology by Morpho originally intended for use in the police and military industry. Now, the Xelios technology provides customers in various industries, including banking, healthcare and stadiums, with solutions for identity authentication, fraud prevention and securing access to facilities and networks.

ScriptPro is a provider of pharmacy management, workflow and telepharmacy systems designed to help pharmacies lower operating costs and reduce dispensing errors.

“We believe that biometric authentication is the simplest and most powerful way to implement controls over pharmacy processes,” Mike Coughlin, ScriptPro president and CEO said. “We have tested a number of these technologies and believe that Xelios has taken this method to a new level of speed and accuracy.”

As recently reported in BiometricUpdate.com, much of the growth in the healthcare biometrics market has been driven by adoption in the private sector. According to Transparency Market Research, the healthcare biometrics market is expected to grow at 33.3% CAGR from 2012 to 2018, with the United States accounting for the majority of the healthcare biometrics market share.

Another recent research report has found that people are generally trusting of some organizations – including healthcare – to use biometrics for identity verification.

Leave a Comment


About Adam Vrankulj

Adam Vrankulj is an editor for BiometricUpdate.com. His background consists of online news writing, editing and content marketing. Adam has written for CBCNews.ca, BlogTO and was the editor and curator for the nextMEDIA and CIX Source publications. He has a degree in journalism and is passionate about science, technology and social innovation. Contact Adam, or follow him at @adamvrankulj